New Fool article on Dyadic DYAI.https://www.fool.com/investing/2020/06/24/this-revolutionary...I hold this stock on the very speculative side of my portfolio.
I'm long on ARCT. It looks like they are pursuing a similar track as Dyadic. Recombinant flu vaccines might be the next "big thing". As opposed to tradition vaccines, they do not require having to grow a vaccine virus sample. Recombinant vaccines are created synthetically and require dramatically less sample per dose. As a result, manufacturing capacity could be ramped up very quickly. Barrons recently made this mention of ARCT:"San Diego-based Arcturus Therapeutics Holdings (ARCT) has been a dark horse in the RNA vaccine race. This week, scientists at Singapore’s Duke-NUS Medical School said that they’ll start clinical trials of the company’s Covid vaccine in the city-state in August.If the vaccine succeeds, Arcturus has a deal with Catalent (CTLT) for production. Hopes for the vaccine and other products have moved H.C. Wainright analyst Ed Arce to rate Arcturus a Buy. Recently trading at $37, the stock could hit $62, he thinks."
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |